Genelux (GNLX) Convertible Debt (2022 - 2023)

Genelux (GNLX) recorded quarterly Convertible Debt of $40000.0 in Q3 2023, down 38.46% quarter-over-quarter from $65000.0 in Q2 2023.

Genelux (GNLX) Convertible Debt (2022 - 2023) Analysis & Trends

Genelux's Convertible Debt history runs 2 years deep, the most recent figure standing at $40000.0 for Q3 2023.

In Q3 2023, Convertible Debt changed N/A year-over-year to $40000.0; the TTM figure through Sep 2023 stood at $40000.0 (changed N/A YoY), while the FY2022 annual figure was $8.5 million, changed N/A from the prior year.
Convertible Debt was $40000.0 for Q3 2023 at Genelux, down from $65000.0 in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $8.5 million in Q4 2022 to a low of $40000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Genelux	129.36 Mn	129.36 Mn	-

Download Data